Lupin and Gan & Lee enter exclusive licensing deal for novel GLP-1 receptor agonist
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
CuraTeQ Biologics and BioFactura USA to terminate agreement mutually
The proceeds from the QIP will be used primarily to accelerate the nationwide expansion of the COCO stores of Davaindia nationwide
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
Ushio, a leader in advanced optical technologies, brings a strong track record and proprietary Photobonding technology
The approval makes AQVESME the only FDA-approved therapy for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia
Afrezza comes in single-use cartridges, delivered via a simple inhaler device. Users select the appropriate cartridge, load it, inhale the insulin, and remove the cartridge
AFib is a progressive condition where timely intervention is critical to disease management and, ultimately, the patient's quality of life
Provides pain relief for more than 30 conditions, including chronic back pain, arthritis, and sports injuries
Subscribe To Our Newsletter & Stay Updated